Moreover, understanding how IGF-II promotes the development of a hormone-independent tumor and its progression into TNBC will be critical for designing novel and more effective targeted therapies badly needed to reduce the breast cancer survival disparity of this disease. Here, IGF2 is linked to breast carcinoma.